HC Wainwright & Co. Reiterates Buy on Avadel Pharmaceuticals, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Avadel Pharmaceuticals, maintaining a price target of $27.
October 31, 2024 | 7:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Avadel Pharmaceuticals, maintaining a price target of $27.
The reiteration of a Buy rating and maintenance of a $27 price target by HC Wainwright & Co. is a positive signal for Avadel Pharmaceuticals. This suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100